Intragenic ERBB2 kinase mutations in tumours

被引：636

作者：

Stephens, P ^{[1
]}

Hunter, C

Bignell, G

Edkins, S

Davies, H

Teague, J

Stevens, C

O'Meara, S

Smith, R

Parker, A

Barthorpe, A

Blow, M

Brackenbury, L

Butler, A

Clarke, O

Cole, J

Dicks, E

Dike, A

Drozd, A

Edwards, K

Forbes, S

Foster, R

Gray, K

Greenman, C

Halliday, K

Hills, K

Kosmidou, V

Lugg, R

Menzies, A

Perry, J

Petty, R

Raine, K

Ratford, L

Shepherd, R

Small, A

Stephens, Y

Tofts, C

Varian, J

West, S

Widaa, S

Yates, A

Brasseur, F

Cooper, CS

Flanagan, AM

Knowles, M

Leung, SY

Louis, DN

Looijenga, LHJ

Malkowicz, B

Pierotti, MA

机构：

[1] Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton CB10 1SA, England

[2] Ludwig Inst Canc Res, B-1200 Brussels, Belgium

[3] Inst Canc Res, Sutton SM2 5NG, Surrey, England

[4] UCL, Inst Orthopaed, Stanmore HA7 4LP, Middx, England

[5] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England

[6] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China

[7] Massachusetts Gen Hosp E, Mol Pathol Unit, Charlestown, MA 02129 USA

[8] Erasmus MC Univ Med Ctr Rotterdam, Dr Daniel Den Hoed Canc Ctr, Josephine Nefkens Inst, Lab Pathol Expt Pathooncol, NL-3000 DR Rotterdam, Netherlands

[9] Univ Penn, Div Urol, Philadelphia, PA 19104 USA

[10] Inst Nazl Tumori, Milan, Italy

[11] Inst Mol Oncol, FIRC, Milan, Italy

[12] Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA

[13] Royal Brisbane Hosp, Queensland Inst Med Res, Herston, Qld 4029, Australia

[14] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA

[15] Royal Brompton Hosp, London SW3 6NP, England

来源：

NATURE | 2004年 / 431卷 / 7008期

关键词：

D O I：

10.1038/431525b

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

[No abstract available]

引用

页码：525 / 526

页数：2

共 8 条

[1] A census of human cancer genes [J].

Futreal, PA ;

Coin, L ;

Marshall, M ;

Down, T ;

Hubbard, T ;

Wooster, R ;

Rahman, N ;

Stratton, MR .

NATURE REVIEWS CANCER, 2004, 4 (03) :177-183

[2] The role of HER2/neu expression and trastuzumab in non-small cell lung cancer [J].

Hirsch, FR ;

Langer, CJ .

SEMINARS IN ONCOLOGY, 2004, 31 (01) :75-82

[3]

Klapper LN, 2000, ADV CANCER RES, V77, P25

[4] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[5] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[6] Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers [J].

Rosell, R .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1171-1173

[7] Opportunities and challenges in the development of kinase inhibitor therapy for cancer [J].

Sawyers, CL .

GENES & DEVELOPMENT, 2003, 17 (24) :2998-3010

[8] HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].

SLAMON, DJ ;

CLARK, GM ;

WONG, SG ;

LEVIN, WJ ;

ULLRICH, A ;

MCGUIRE, WL .

SCIENCE, 1987, 235 (4785) :177-182

← 1 →